Key Takeaways AbbVie agreed to license a weight-loss drug in development from Danish biotech firm Gubra.AbbVie said it will ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the ...

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

Yahoo Finance host Josh Lipton tracks the day's biggest stocks in this Market Minute. AbbVie (ABBV) announced a licensing ...